News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Pays $181 Million to States for Risperdal Marketing


8/31/2012 6:35:06 AM

Thirty-six states and the District of Columbia will share in $181 million that Johnson & Johnson has agreed to pay to resolve allegations of inappropriate marketing of the antipsychotic drug Risperdal. Pennsylvania, New Jersey, and Delaware are among the states that filed similar complaints in their own courts Thursday and will get $8.4 million, $5.3 million, and $4.2 million, respectively. New York will get $9 million. Johnson & Johnson has headquarters in New Brunswick, N.J.; its Janssen Pharmaceuticals subsidiary, which makes Risperdal, is based in Titusville.

Read at Philadelphia Inquirer
Read at Seattle Post-Intelligencer
Read at App.com
Read at BusinessWeek
Read at nj.com
Read at NewsDay


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES